SUPPLEMENTARY DATA

**Supplementary Figure 1.** MLDS-diabetes is T-cell mediated. Diabetes incidence of WT mice treated with the T-cell depleting monoclonal antibody KT3 (□, n=6) or saline (■, n=6). ****P*<0.001.



SUPPLEMENTARY DATA

**Supplementary Figure 2.** Confirmation of reconstitution of BM chimeric mice. Representative FACS profiles of human CD39 (hCD39) expression on peripheral blood leukocytes from 9-week old chimeric mice. Black – CD39TG control; Grey – WT control; Dotted black –$CD39TG_{WTBM}$.



SUPPLEMENTARY DATA

**Supplementary Figure 3.** A1R does not play a role in the pathogenesis of MLDS-induced diabetes A. Diabetes incidence of WT mice treated with A1Ri (□, n=4) or vehicle (0.1% DMSO) (■, n=6). ns – not significant. B. Diabetes incidence of WT mice treated with A1Rag (□, n=6) or saline (■, n=4). ns – not significant.



SUPPLEMENTARY DATA

**Supplementary Figure 4.** Confirmation of genotype in the A2AR KO/CD39 TG progeny. A. Representative FACS profile of peripheral blood leukocytes of 5-week old A2ARKO/CD39TG mice, stained with FITC-conjugated anti-human CD39. Dotted black – progeny; Grey – WT control; Black – CD39TG control B. PCR analysis of genomic DNA from offspring of the A2ARKO/CD39TG cross.
C. Primers and primer sequences used in B.

**A**



SUPPLEMENTARY DATA

**B**




**C**

| Primer | Specificity | Sequence |
|---|---|---|
| A2A WT-F | WT sequence | AGCCAGGGGTTACATCTGTG |
| A2A WT-R | WT sequence | TACAGACAGCCTCGACATGTG |
| Neo 2-F | A2ARKO sequence | TCGGCCATTGAACAAGATGG |
| Neo 3-R | A2ARKO sequence | GAGCAAGGTGAGATGACAGG |